LifeMatrix Technologies AG will use the CHF 150,000 to expand the clinical launch strategy and support regulatory submissions.
LifeMatrix Technologies AG will use the CHF 150,000 to expand the clinical launch strategy and support regulatory submissions.
For newsletter distribution, your email address will be processed by a GDPR-certified service provider. Further information can be found in our privacy policy.